Larimar Therapeutics Inc.
Clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Larimar Therapeutics Inc. is a clinical-stage biotechnology company founded in 2005. It is focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently undergoing evaluation in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Moreover, Larimar plans to utilize its intracellular delivery platform to design other fusion proteins aiming to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
As of 14 February 2024, Larimar Therapeutics announced a Post-IPO Equity investment amounting to $172.50 million. The investors behind this latest funding round were not disclosed. The company is headquartered in the United States. For more information, please visit: https://larimartx.com.
In summary, Larimar Therapeutics Inc. is making significant strides in developing novel treatments for rare diseases, with promising progress in the clinical evaluation of CTI-1601. The recent Post-IPO Equity investment further underlines the confidence and support from investors in the company's endeavors, signaling potential growth and impact in the biotechnology industry.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $172.50M | - | 14 Feb 2024 | |
| Post-IPO Equity | $70.00M | 1 | Deerfield | 14 Sep 2022 |
| Post-IPO Equity | $95.00M | 7 |
|
21 May 2021 |
| Post-IPO Equity | $60.00M | - | 28 Jun 2018 | |
| Debt Financing | $20.00M | 2 |
|
17 Apr 2014 |
No recent news or press coverage available for Larimar Therapeutics Inc..
We care about your data, and we'd love to use cookies make your experience better.
